1448893-31-9

Upstream product

• 99-90-1 para-bromoacetophenone 
• 1448893-28-4 (S)-1-(4-bromophenyl)ethyl diisopropylcarbamate 
• 1448893-30-8 (R)-2-(4-bromophenyl)-2-cyclopropylpropanal 
• 5391-88-8 (S)-1-(4-bromophenyl)ethanol 

Downstream Products

• 1360551-95-6 (R)-2-(4-bromophenyl)-2-cyclopropyl-N′-hydroxypropanimidamide 
• 1360552-09-5 (R,Z)-2-(4-(2-aminopyrimidin-5-yl)phenyl)-2-cyclopropyl-N′-hydroxypropanimidamide 
• 1360549-37-6 5-(4-{(R)-1-cyclopropyl-1-[5-(1H-pyrazol-4-yl)-[1,2,4]oxadiazol-3-yl]ethyl}phenyl)pyrimidin-2-ylamine 
• 1360550-04-4 2-[4-(3-{(1R)-1-[4-(2-aminopyrimidin-5-yl)phenyl]-1-cyclopropylethyl}-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl]-N,N-dimethylacetamide 

Relevant academic research and scientific papers

Development of an asymmetric synthesis of a chiral quaternary FLAP inhibitor

A practical sequence involving a noncryogenic stereospecific boronate rearrangement followed by a robust formylation with an in situ generated DCM anion has been developed for the asymmetric construction of an all-carbon quaternary stereogenic center of a FLAP inhibitor. The key boronate rearrangement was rendered noncryogenic and robust by using LDA as the base and instituting an in situ trapping of the unstable lithiated benzylic carbamate with the boronic ester. A similar strategy was implemented for the DCM formylation reaction. It was found that the 1,2-boronate rearrangement for the formylation reaction could be temperature-controlled, thus preventing overaddition of the DCM anion and rendering the process reproducible. The robust stereospecific boronate rearrangement and formylation were utilized for the practical asymmetric synthesis of a chiral quaternary FLAP inhibitor.

PROCESS FOR PREPARING CARBOXAMIDINE COMPOUNDS

The present invention relates to a process of making a compound of formula (I): Wherein, R1, R2, R4 and X are as defined herein.